drugset / Trial / NCT00568022
A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase II dose of ixabepilone in combination with capecitabine in Japanese participants with metastatic breast cancer.
Timeline
- Start
- 2008-02
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixabepilone | Small molecule | 32 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 40 mg/m2 | Intravenous |
| Background | Capecitabine | Small molecule | 1650 mg/m2 | Oral |
| Background | Capecitabine | Small molecule | 2000 mg/m2 | Oral |